NCT01111825 2018-09-26Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerPuma Biotechnology, Inc.Phase 1/2 Completed99 enrolled 14 charts
NCT00699491 2018-06-13Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerNational Cancer Institute (NCI)Phase 1/2 Completed48 enrolled 14 charts